Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Lexaria Expands into Transdermal, Grows Licensing Revenue -- CFN Media
SEATTLE, April 04, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Lexaria Bioscience Corp.’s (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQB:LXRP) DehydraTECH™ which represents a breakthrough in cannabinoid drug delivery. Lexaria’s DehydraTECH™ is technology that promotes a molecular association between cannabinoids and certain fatty acid compounds that are known to have palatability and bio-absorption enhancing properties. This combination, in turn, results in improved cannabinoid taste, bioavailability and speed of effectiveness.
In the quickly expanding legal cannabis industry, effective delivery of the drug is an ongoing problem. Many consumers have taken to edible products as a healthier alternative to smoking, but there are still key issues with bioavailability and taste when infusing cannabinoids. Other delivery methods have gained in popularity as well, including topical creams and lotions. In addition to improving intestinal bio-absorption by as much as five to ten times in as little as 15 minutes, new laboratory study data has shown that the DehydraTECH™ technology is just as promising when it comes to transdermal applications.
In March, the company announced the results from its first laboratory study of DehydraTECH™ on human skin at a California-based laboratory specializing in Franz diffusion cell skin permeability testing. Researchers compared the technology with two leading skin penetration enhancers, looking for penetration time, absorption quantity, and peak amounts of CBD absorbed into and through the skin at multiple testing intervals over 48 hours.
The researchers found that DehydraTECH™ was the fastest acting for absorption into the skin and demonstrated the highest overall average quantity of CBD delivered through the skin. In fact, the technology outperformed competing products by as much as 225%. The technology also lacked any odor, even without the use of perfumes, contrary to other cannabinoid industry products that can be quite odoriferous without the use of masking perfumes.
“We have theorized for some time that our DehydraTECH™ delivery system might have positive effects on skin-based delivery complementing its already commercialized gastro-intestinal product applications,” said Lexaria President John Docherty. “The first round of testing was very encouraging and showed clear benefits with regards to speed of action and, particularly, delivery of CBD across the skin barrier for potential transdermal applications.”
Building an IP Portfolio
Lexaria has already begun to commercialize the DehydraTECH™ delivery system, as well as build up its patent portfolio. Earlier this year, the company entered into two licensing agreements for the innovative platform with a cannabis edibles maker and a Canadian cannabis chocolate manufacturer. Under these agreements, the company has licensed out its technology for the development of edible products in exchange for licensing fees and royalties.
On March 22, the company announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office providing for a “composition of matter” claims that protect the specific combination of substances which enable improved taste and bio-absorption. This adds to the company’s existing “method of use” patent that had previously been granted, further protects its delivery system, and opens the door to further commercialization.
“This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH™ technology,” said Mr. Docherty. “This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed.”
Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP) represents a compelling investment opportunity in the cannabis industry. By solving a key issue facing many edibles manufacturers, the company hopes to license its technology to a growing number of companies in exchange for licensing fees and royalties. These high-margin revenues could unlock significant value for shareholders over the long-term.
For more information, visit the company’s website or download their investor presentation.
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Another patent award coming, news out this morning
KELOWNA, BC / ACCESSWIRE / March 22, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received a new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") providing for "composition of matter" claims that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH™ technology for the delivery of cannabinoids. This is a significant addition to Lexaria's existing manufacturing "method of use" patent rights previously granted.
"This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH™ technology," said John Docherty, President. "This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed demonstrating its significant bioavailability performance enhancement properties."
Under USPTO practice, there is no opposition period between allowance and issuance. The patent application number is 15/225,802, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof." As has been Lexaria's experience in the past, the Company expects the formal granting of the new patent within roughly one hundred days or less.
Lexaria has additional patent applications that remain within the USPTO process, of both the composition of matter and process varieties. Lexaria will continue to develop and strengthen its patent portfolio in the USA, Canada, and internationally and expects further patent awards this year. As its patent portfolio increases, Lexaria will be better able to commercialize its technologies and defend its intellectual property.
Lexaria's patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredient ("API") substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long-term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Sounds like different process that LXX, absorption through the blood stream compared to LXX through digestion.
News out this morning
Lexaria Files New Patent Application for Enhanced Transdermal Delivery System
KELOWNA, BC / ACCESSWIRE / March 20, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce it has filed a new patent application with the United States Patent and Trademark Office (''USPTO'') for use of DehydraTECHTM to improve the speed and quantity of absorption of active pharmaceutical ingredients (''API'') through the skin.
The patent application follows the recently announced successful laboratory evaluation of DehydraTECHTM in the transdermal delivery of cannabidiol (''CBD'') that showed as much as a 225% increase in CBD permeability compared to control formulations tested with leading commercial penetration enhancers; and almost a 1,900% increase in CBD permeability compared to a control formulation that was devoid of both the DehydraTECHTM technology or any commercial penetration enhancers. The original research protocols were overseen by Lexaria President John Docherty and represent a unique, new and improved method of transdermal delivery for cannabinoids and potentially many other active ingredients.
In the patent application, Lexaria has applied for patent protection for the delivery of all of the active ingredient classes already identified in its other issued and pending patent applications including cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and phosphodiesterase inhibitors, as well as a broad range of additional active ingredients commonly found in topical products today that may benefit from enhanced skin permeability performance in concert with the DehydraTECHTM technology.
The Company believes that its DehydraTECHTM technology could drive significant innovation and improvement for the delivery of active ingredients through topical products, transdermal patches, cosmetics and many other skin-oriented consumer product formats. Lexaria will initiate third-party licensing discussions for this new transdermal application of DehyrdaTECHTM as soon as possible.
Lexaria's patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used API substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.
“This newly issued patent is the most valuable and difficult to obtain relative to the other four patents that the Company has been previously issued,” said Dr. Pankaj Modi, CEO of CTTH. “The claims allowed are so broad that virtually any entity in Canada that comes to market with a strip, wafer, tablet, or gum that has any active therapeutic molecule such as cannabinoids or opioids will be infringing upon our patent. The nanonization of cannabinoids and opioids through our Fast Dissolving Oral Thin Film sub-lingual wafers will provide the Company and its licensed Canadian distribution partner the opportunity to dominate and monopolize this industry in Canada. This patent also allows for the introduction of opioid reduction formulations whereby 10% to 25% of the opioid analgesics dose can be combined with 75% to 90% cannabinoids like THC and/or CBD which would reduce opioid consumption and overdosing possibilities and improve the safety profile of daily multiple doses of pain medications.”
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
another interesting tidbit in the Post
The Financial Post reports in its Thursday edition that major alcohol companies will likely see sales squeezed by legal cannabis in the coming years, according to research firm CFRA Research. The Post's Mark Rendell writes that CFRA analyst Joe Agnese says, "Due to shared usage occasions, we view the legalization of cannabis as a threat to alcohol industry consumption growth." Mr. Agnese cites AnheuserBusch InBev, The Boston Beer Company and Brown-Forman, best known for Jack Daniels Tennessee Whiskey, as companies that could see a decline in product consumption. Mr. Agnese says: ""When I consider the use indications of the alcohol industry -- when it's consumed, who consumes it, that type of environment -- alcohol overlaps significantly with cannabis, whereas something like tobacco doesn't. While you are going to see a big shift from the illegal (cannabis) market to the legal market, you're also going to have a lot of alcohol consumers who don't consider cannabis, because it's illegal, moving over to consuming cannabis, especially with the development of closer alternatives such as infused beverages. ... Canada's going to be just a wonderful test market for the U.S. to see how it all plays out."
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Interesting news today
The Financial Post reports in its Wednesday edition that Canada fell to a surprise second place behind the United Kingdom in 2016 legal cannabis production. The Post's Mark Rendell writes that according to a U.N.-backed report, the U.K. produced 95,000 kilograms of legal marijuana in 2016, compared with Canada's 80,732 kilograms. The U.K. exported 2,100 kilograms, 67.7 per cent of the global total; Canada moved less the 100 kilograms across borders in 2016. The U.K.'s finish at the top of the pile is unexpected, given the country has no legal medical cannabis framework. It does, however, allow the cannabis-based product Sativex, which is produced by GW Pharmaceuticals, for multiple sclerosis treatment.
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
CIMA, seems the CTT patent is a lot different than LXX, to do with wafers. I looked at their clinical study info and it appears that it does not work as well as vaporizing. I don't get what big advantage they have other than wafers might be preferred over smoking, but if it is not as good as vaporizing, what is the big deal??